- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- IFX-1, Placebo
- Drug
- Lead sponsor
- InflaRx GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Fort Myers, Florida • Miami, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
- Interventions
- IFX-1 low dose, IFX-1 high dose, Placebo
- Drug
- Lead sponsor
- InflaRx GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 33
- States / cities
- Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more
- Conditions
- Pyoderma Gangrenosum
- Interventions
- vilobelimab
- Drug
- Lead sponsor
- InflaRx GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Sacramento, California • Miami, Florida • Tampa, Florida + 4 more
- Conditions
- SCC - Squamous Cell Carcinoma of Skin
- Interventions
- Vilobelimab, Vilobelimab + pembrolizumab combination therapy
- Drug
- Lead sponsor
- InflaRx GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- La Jolla, California • Aurora, Colorado • Miami, Florida + 3 more
- Conditions
- Pyoderma Gangrenosum
- Interventions
- vilobelimab, Placebo
- Drug
- Lead sponsor
- InflaRx GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 12
- States / cities
- Hialeah, Florida • Miami, Florida • Orlando, Florida + 9 more
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Interventions
- Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo
- Drug
- Lead sponsor
- PPD Development, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Interventions
- Cohort A: vilobelimab, Cohort A: placebo
- Drug
- Lead sponsor
- PPD Development, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more